420
Participants
Start Date
May 4, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
AK112 Injection
Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
Placebo Injection
Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
NYU Langone Laura and Isaac Perlmutter Cancer Center, New York
Mount Sinai, New York
New York Oncology/Hematology, Clifton Park
Hospital Teresa Herrera, A Coruña
Istituto Nazionale dei Tumori, Milan
Instituto Europeo di Oncologia, Milan
American Oncology Partners, Bethesda
Virginia Cancer specialisits, Fairfax
Lucus Augusti University Hospital, Lugo
Hospital General Universitario Gregorio Maranon, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario Clinico San Carlos, Madrid
Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz, Madrid
Hospital Universitario La Paz, Madrid
Puerta de Hierro University Hospital, Majadahonda
Hospital Regional Universitario de Malaga, Málaga
Medical University South Carolina, Charleston
University of Miami, Miami
The Oncology Institute of Hope & Innovation, Fort Lauderdale
BRCR Global, Tamarac
BRCR Global, Plantation
Florida Cancer Specialists -East, West Palm Beach
Florida Cancer Specialists - North, St. Petersburg
Florida Cancer Associates - Ocala Oncology, Ocala
omplejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Las Palmas
Baptist Hospital, Memphis
Hospital Universitario Nuestro Senora de Valme, Seville
University Hospital of Parma, Parma
Zangmeister Cancer Center, Columbus
Oncology Hematology Care, Fairfield
HealthPartners Cancer Research Center, Saint Paul
Sanford Roger Maris Cancer Center, Fargo
Léon Bérard Cancer Center, Lyon, Lyon
Hematology/Oncology Clinic - SCRI, Baton Rouge
Hospital Bichat-Claude Bernard, Paris
Texas Oncology Baylor Charles A. Sammons Cancer Center, Dallas
Institut Curie, Paris
MD Anderson University of Texas, Houston
Texas Oncology Webster, Webster
Texas Oncology South Austin, Austin
Rocky Mountain Cancer Center, Lone Tree
University of Southern California, Los Angeles
Valkyrie Clinical Trials, Los Angeles
UCLA Department of Medicine - Hematology/Oncology, Los Angeles
Presbyterian Intercommunity Hospital, Whittier
UC San Diego, La Jolla
Sharp Memorial Hospital, San Diego
Providence St. Joseph, Orange
UC Irvine, Orange
CBCC Global Research, Bakersfield
CHI Creteil, Créteil
Palo Alto Medical Foundation Research Institute, Mountain View
California Pacific Medical Center, San Francisco
Gustave Roussy Cancer, Villejuif
Providence Medical Foundation, Santa Rosa
Sutter Cancer center, Sacramento
UC DAVIS Comprehensive Cancer Center, Sacramento
Kaiser Permanente Northwest, Portland
Williamette Valley Cancer Institute and Research, Eugene
Compass Oncology, Vancouver
New England Cancer Specialists, Scarborough
Dana Farber Cancer Institute, Boston
Cross cancer Institute, Edmonton
BC Cancer, Vancouver
Lung Cancer Canada, Ottawa
Princess Margaret Cancer Centre, Toronto
Allan Blaire Cancer Centre, Regina
Universite Hospital Laval, Québec
Campus Bio-Medico University, Roma
Istituto Nazionale Tumori, Regina Elena, Rome
Vall d'Hebron Institute of Oncology, Barcelona
Badalona-Hospital Germans Trias i Pujol, Barcelona
The Royal Marsden, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Collaborators (1)
Akeso
INDUSTRY
Summit Therapeutics
INDUSTRY